Sanford Laboratories for Innovative Medicines
Sanford Laboratories for Innovative Medicines, a subsidiary of Johnson & Johnson, operates as a key player in the pharmaceutical and biotechnology sectors, focusing on the development and manufacturing of advanced therapies.
Profile
Develops and manufactures advanced gene therapies and innovative medicines.
Sanford Laboratories for Innovative Medicines, a subsidiary of Johnson & Johnson, operates as a key player in the pharmaceutical and biotechnology sectors, focusing on the development and manufacturing of advanced therapies. Founded as part of Johnson & Johnson's broader strategy to enhance its Innovative Medicine division, Sanford Labs has grown to become a critical hub for the production of gene therapies and other cutting-edge treatments. The facility, located in Sanford, North Carolina, spans 135,000 square feet and is designed to support both clinical and commercial-scale manufacturing of adeno-associated virus (AAV) vectors for gene therapies.
In 2025, Johnson & Johnson reported operational sales growth of 5.3% in its Innovative Medicine division, with sales exceeding $60 billion for the first time, driven by high-performing brands like DARZALEX and CARVYKTI. Sanford Labs plays a pivotal role in this growth, particularly in the oncology and immunology sectors, where it supports the production of therapies that have shown transformative potential. The lab's state-of-the-art capabilities and integration into Johnson & Johnson's global supply chain underscore its importance in the company's strategy to shape the future of healthcare.
Who buys this
- Pharmaceutical companies
- Biotechnology firms
- Healthcare providers
- Research institutions
- Patients with genetic disorders
Strengths and what to watch
Strengths
- Integrated into Johnson & Johnson's global supply chain, ensuring robust support and resources.
- State-of-the-art manufacturing facility capable of clinical and commercial-scale production.
- Focus on high-growth areas like oncology and immunology, with a strong pipeline of innovative therapies.
Watch for
- Dependence on Johnson & Johnson's broader strategy, which could shift focus away from gene therapies.
- Regulatory challenges in gene therapy manufacturing and approval processes.
- Potential for operational disruptions due to the complexity of manufacturing advanced therapies.
Key Information
- Headquarters
- Sanford, North Carolina
Frequently Asked Questions
What is Sanford Laboratories for Innovative Medicines?
Sanford Laboratories is a Johnson & Johnson subsidiary specializing in gene therapy and innovative medicine manufacturing. The 135,000 sq ft North Carolina facility produces adeno-associated virus (AAV) vectors for therapies, focusing on oncology and immunology. It supports both clinical and commercial-scale production.
Who owns Sanford Laboratories for Innovative Medicines?
Sanford Laboratories operates as part of Johnson & Johnson's Innovative Medicine division. The parent company reported $60B+ in 2025 sales for this segment, with Sanford Labs contributing to growth through advanced therapy manufacturing, particularly for high-performing brands like DARZALEX and CARVYKTI.
Where is Sanford Laboratories located?
The 135,000 square foot manufacturing facility is situated in Sanford, North Carolina. This strategic location serves as a hub for clinical and commercial-scale production of gene therapies, particularly AAV vectors, supporting Johnson & Johnson's global biopharmaceutical supply chain.
What does Sanford Laboratories manufacture?
The facility specializes in adeno-associated virus (AAV) vector production for gene therapies, with capabilities spanning clinical trials to commercial-scale manufacturing. Its focus areas include oncology and immunology treatments, supporting transformative therapies like CARVYKTI through advanced bioprocessing technologies.
How big is Sanford Laboratories' facility?
The Sanford, NC campus spans 135,000 square feet, housing state-of-the-art biomanufacturing capabilities. This space supports end-to-end production of advanced therapies, from research-scale batches to full commercial manufacturing, with integrated quality control systems.
What therapies has Sanford Laboratories helped develop?
Sanford Labs contributes to Johnson & Johnson's oncology and immunology portfolio, including therapies like CARVYKTI and DARZALEX. Its AAV vector manufacturing capabilities support gene therapies showing transformative potential for genetic disorders, aligning with the parent company's $60B+ Innovative Medicine division growth.
Sources
- www.sec.gov — Johnson & Johnson's 2025 annual report detailing operational sales growth and focus on innovative medicines.
- www.prnewswire.com — Details on the opening of the Sanford facility and its role in gene therapy manufacturing.
- www.prnewswire.com — Information on the integration of Audentes Therapeutics into Astellas Gene Therapies and the expansion of operations.
- www.prnewswire.com — Details on Astellas' collaboration with Dyno Therapeutics to develop next-generation AAV vectors.